Your source for all Prime Therapeutics' February 2026 Drug Insights publications.

Prime Therapeutics (Prime) provides you with regular updates on the drug pipeline as well as next-generation clinical information and hot topics. The following Drug Insights publications for February 2026 will keep you informed on what’s trending now and trending clinical topics. 

---

Released Feb. 3, 2026

Watch List

A monthly report of the most notable drugs that may significantly affect the populations we serve. Drug highlights this month are marnetegragene autotemcel, pariglasgene brecaparvovec and more.

---

Released Feb. 11, 2026

FDA Decisions Expected: March 2026

A breakdown of FDA decisions expected of new drugs anticipated to hit the market, this edition covers bulevirtide, tebipenem HBr and more.

---

Released Feb. 13, 2026

Oncology Insights

Featuring commentary by Caroline Quinn, PharmD, BCOP, on developments in the oncology space, this installment examines how recent approvals of subcutaneous fomulatations of certain drugs represents a shift in immune checkpoint inhibitor delivery. 

---

Released Feb. 19, 2026

High-Cost Therapy Profile

Providing a clinical deep dive into a select high-cost drug in the pipeline, this month's profile features INO-3107, an investigational DNA immunotherapy designed to elicit an antigen-specific T cell response targeting human papillomavirus (HPV)-6.

---

Released Feb. 26, 2026

Trending Topics & Drug Approvals: February 2026

Prime covers hot topics and the latest specialty and traditional drug approvals. The latest edition covers the American Academy of Pediatrics' (AAP) recommended childhood and adolescent immunization schedule for 2026.

---

Looking for previous 2026 drug insights publications?

Simply click on the month to access past editions of our drug insights.

January 2026